WO2010079513A2 - Traitement sans douleur des verrues, cors et durillons - Google Patents

Traitement sans douleur des verrues, cors et durillons Download PDF

Info

Publication number
WO2010079513A2
WO2010079513A2 PCT/IN2010/000001 IN2010000001W WO2010079513A2 WO 2010079513 A2 WO2010079513 A2 WO 2010079513A2 IN 2010000001 W IN2010000001 W IN 2010000001W WO 2010079513 A2 WO2010079513 A2 WO 2010079513A2
Authority
WO
WIPO (PCT)
Prior art keywords
warts
wart
sulfide
treatment
lidocaine
Prior art date
Application number
PCT/IN2010/000001
Other languages
English (en)
Other versions
WO2010079513A3 (fr
Inventor
Sanjay Banerji
Original Assignee
Sanjay Banerji
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanjay Banerji filed Critical Sanjay Banerji
Publication of WO2010079513A2 publication Critical patent/WO2010079513A2/fr
Publication of WO2010079513A3 publication Critical patent/WO2010079513A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients

Definitions

  • This invention relates to a painless topical treatment for varied dermatological conditions characterized by hyperkeratosis such as warts corns and callus.
  • the present invention comprises of two carrier system (1) Soluble sulfide of alkali or alkaline earth metals or a combination thereof in a polar and/or semi polar solvent in an inert atmosphere and (2)Eutectic mixture of Lidocaine and Prilocaine in an oil in water emulsion to be used for topical painless treatment of various dermatological conditions characterized by massive hyperkeratosis including but not limiting to Warts, corns and callus.
  • the sulfide component in the composition dissolves the hyperkeratotic epidermis thereby facilitates the penetration of the topical anesthetic component which otherwise is not possible as it is well perceived that EMLA containing eutectic mixture of Lidocaine and Prilocaine does not produce the desired anesthesia when there is hyperkeratotic epidermis as that over the planter and palmer surface and in these areas the injections shots are more painful .
  • Warts are a common affliction, estimated to affect as many as seven to twelve percent of the population.
  • Human papillomavirus (HPV) is the causative agent of warts.
  • warts can be spread to other parts of the body or to other persons through skin-to-skin contact or contact with a surface contaminated with HPV. Most warts generally do not lead to serious disease . Warts are more commonly diagnosed based on their physical appearances and locations on the body. Generally, five different types of warts are classified by their clinical presentation. Common warts (Le. verrucae vulgaris) are domed, irregularly surfaced lesions those display hyperkeratosis and may occur anywhere on the body, but typically not including genital regions, mucous membranes or plantar surfaces (soles or bottoms of the feet). Periungual warts occur on the skin surrounding finger and toe nails.
  • Permanent nail deformity can occur where the wart physically contacts the nail or invades the nail space from the underside. Deformity can also occur when the wart involves the nail folds or cuticles or affects the nail matrix.
  • Flat warts i.e. verrucae planae usually occur on the face, trunk and extremities. They often occur on the faces and extremities of children and on the lower legs of women.
  • Plantar warts (Le. verrucae plantares) occur only on the soles of the feet. Such warts typically become callused and grow into the foot due to the forces exerted on the foot from everyday movement. Plantar warts may often be associated with pain.
  • Corns are a painful type of hyperkeratosis, found principally over prominent toe joints and between toes.
  • Heloma Durum hard corn
  • Heloma Molle soft corn
  • the soft corn results from pressure exerted between adjacent toes and is soft due to moisture between the toes.
  • a callus may be a diffuse or circumscribed area of hyperkeratosis at a site of repeated pressure and friction.
  • the current standard treatment of warts on non-genital sites involves primarily physical destruction of the infected cells. This destruction is performed by a number of different modalities, including chemical destruction, cryosurgery, electro surgery, laser surgery, pharmacological agents, and immunotherapy.
  • Salicylic Acid Though the use of topical salicyclic acid still remains a first- line treatment for warts on the hands and feet the usual time period required for removal may extend to 3 months and the application may cause excessive destruction to normal tissue. There are numerous commercial preparations, both over the counter and by prescription, of salicylic acid in various vehicles and concentrations ranging from 15% to 40%.
  • Another treatment approach involves the use of 40% salicylic acid in a plaster dressing that is applied to the wart for 48 hours, followed by 48 hours of no therapy. Recently, 15% salicylic acid has been placed in a karaya gum patch. The patch is then applied to the wart on a nightly basis. According to Micheael T.Goldfarb et al in Dermatologic clinic Vol..9 No. 2 , April 1991 the success rate of these simple procedures is satisfactory. After 3 months of use, warts in 67% of patients with hand warts, 84% with simple plantar warts, and 45% with mosaic plantar warts are completely resolved. The mechanism of action of salicylic acid is keratolysis of the virally infected tissue. The risk of the this treatment is local irritation itch may demand discontinuation of treatment
  • Formalin Another topical medication that can be prescribed for the treatment of planter warts is formalin.
  • Formalin is 37% formaldehyde in water and is used in concentrations of 2% to 3%. It is used primarily for treating plantar warts on weight-bearing areas where the keratin is extremely thick. Formalin is drying and causes unacceptable cracking and pain on thinner skin areas. The mechanism of action of formalin is destruction of the wart-infected tissue by dehydrations.
  • Glutaraldehyde also has been used topically in much the same way as formaldehyde for the treatment of warts. It is effective as a 10% solution and has had a success rate similar to that of topical salicylic acid. Side effects are similar to these of formalin therapy, including drying and fissuring of the skin as well as the possibility of sensitization to glutaraldehyde. In addition, glutaraldehyde turns the skin brown, and the patient must be made aware of this to avoid concern.
  • caustic acids including monochloracetic, bichloroacetic, and trichloroacetic and at concentrations of 50%, is a useful office treatment for warts. They are powerful irritants that work by hydrolyzing the cellular protein, which leads to inflammation and cell death. These acids do not bind preferentially to the wart-infected cells and can cause destruction and produce scaring of the surrounding normal skin if not carefully applied. Therefore, these agents are to be applied only by the physician, and this therapy is best reserved for deep plantar warts.
  • caustic acids are applied to the involved area with a stick application after any keratotic debris has been pared away. The area is then occluded with tape, which is left in place for approximately 2 hours. Therapy is repeated on a weekly basis until the wart is cured.
  • CRYOSURGERY One of the most commonly performed office procedure for the treatment of warts is cryotherapy. It is effective for warts on any site.
  • the two most commonly used agents are carbon dioxide snow, which has a melting point of- 56.6o C, and liquid nitrogen, which vaporizes at - 195.80
  • C. Cryotherapy works mainly by destroying the host cell and stimulating an immune response to the area.
  • Carbon dioxide snow or dry ice, is obtained by passing carbon dioxide gas rapidly through a cylinder. It can be formed into a carbon dioxide stick with a mold, which should be smaller than the wart. Carbon dioxide snow can also be made into a slush by adding a few drops of acetone; it is applied to the wart with a cotton-tipped applicator.
  • Liquid Nitrogen is available in flasks those can maintain the liquid nitrogen for months.
  • the lower temperature of liquid nitrogen compared with carbon-tipped applicator or by the use of a liquid nitrogen spray delivered by a number of commercially available handheld units.
  • cryosurgery on the lateral aspects of digits may result in sensory loss.
  • the use of cryosurgery on darkly pigmented individuals may lead to areas of depigmentation, which often take months to resolve. In contrast, some patients even have areas of hyperpigmentation, which also may persist for a long period. Therefore a careful discussion of possible problems with cryotherapy should be carried out prior to treatment SURGICAL REMOVAL
  • Electrosurgery Certain warts that have been resistant to chemical surgery and cryosurgery are possible candidates for electrosurgery. Solitary warts on the scalp, face, neck, mouth, elbows, knees, and torso are easily removed by electrosurgery; however, electrosurgery should be avoided for treatment of warts on the plantar surface because of painful scarring. In addition, treating periungual warts with electrosurgery can cause nail dystrophy.
  • the wart Prior to electrosurgery, the wart must be anesthetized with a local infection, usually 1% lidocaine without epinephrine. The wart is then electrodesicated with the use of an electrosurgery until until it turns white, with some charring on top. The charred wart tissue is then removed, usually with a curette. After completing the procedure, it may appear that the wart has been completely removed; however, recurrence rates are no lower than those with the other therapies previously mentioned. The pain associated with administration of local anesthetic is excruciable becaude of the thickned palmer and planter skin
  • Pondophyllin- Podophyllin is a complex resin mixture that not only has been used for the treatment of genital warts but also has proved to be successful for plantar warts.
  • Podophyllin is a crude extract that can be derived from two plant species, Podophyllum peltatum and Podophyllum emodi. Pondophyllin probably exerts its beneficial effect in the treatment of warts by two mechanisms : Pondophyllin in a 25% liquid paraffin preparation can be painted on a plantar wart after the excess keratin has been pared away with a scalpel. The treatment site is then covered by an adhesive plaster and left undisturbed for 1 week or until pain develops.
  • Podophyllin has been associated with systemic toxicity, especially when used in treating genital warts. These systemic side effects range from nausea and vomiting to neurologic complications including seizures, coma, and peripheral neuropathy. Fatality has been reported with the use of the topical resin, in only one incident with application to a large surface area, whereas other reported cases of death have followed ingestion of the resin. Podophyllin is not a standardized preparation. A typical 25% podophylin resin solution may contain a wide variation in concentration of its primary active ingredient, podophyllotoxin, from a little as 2% to as much as 10%. Because of the potential toxicity and wide variability of this agent, application of podophyllin resin has largely remained an office procedure.
  • podophyllin is a purified solution of podophyllotoxin. Instead of a wide variation of concentration of active ingredients, as is possible with the standardized podophyllotoxin solution, the physician knows exactly what strength of medications is being used. This makes side effects more predictable and even allows home application of the product by the patient.
  • podophyllotoxin has been used successfully by applying a 0.5% solution in alcohol to genital warts in men. Purified podophyllotoxin preparation appears to have a far-better safety profile when compared with that of the resin.
  • the major problem with podophyllotoxin is a local reaction that largely appears to be irritant in nature and includes mild erythema, burning, tenderness, and an occasional erosion. It appears to be most effective for treating warts that are also successfully treated by podophyllin resin, primarily those of the genitalia.
  • Cantharidin derived from the blister beetle, is a powerful vesiculating agent and a proven topical, therapy for almost all nongenital warts. It acts by poisoning mitochonria, thus causing epidermal cell death and acantholysis.
  • Cantharidin- Cantharidin derived from blister beetle is a powerful vesiculating agent and has been used for treatment of warts.
  • a standard therapeutic regimen involves application of cantharidin 0.7% collodion solution to the wart and then occlusion of the area with a small piece of adhesive tape for 24 hours. When the tape is removed, a blister is usually present and heals over the following week.
  • One treatment is often adequate for the complete destruction of the wart; however, repeat therapy is frequently necessary and is performed at intervals ranging from 1 to 3 weeks. The major side effect from this treatment is pain from the blister.
  • 5-Fluorouracil (5-Fu) The antimetabolite agent 5-FU is commonly used topically for the treatment of actinic keratoses.
  • Topical 5-FU has been used most successfully for the treatment of verruca plana with a cure rate of 80% of patients with recalcitrant disease; however, its overall cure rates of only 50% and 60% for plantar warts and common warts of the hands, respectively, have been disappointing.
  • 5-FU The mechanism of action of 5-FU is probably due to its affinity for abnormal keratinocytes and their subsequent destruciton by inhibition of DNA and RNA synthesis as well as an immunostimulatory action.
  • the side effects of 5- FU primarily include hyperpigmentation, erythema, and erosions.
  • the erythema and erosions disappear completely after discuntinution of therapy and sometimes require the short-term application of a low-ptency topical corticosteroid.
  • Hypergpigmentation may be troublesome and may remain for a long period after discuntinuation of the medication. This is a greater problem in nonwhite patients, and patients should be warned of this possible complication.
  • Bleomycin is a combination of polypeptide antobiotics first isolated from a soil fungus, Streptomyces verticillus. This mixture exhibits cytotoxoid activity and inhibits DNA synthesis in both cells and viruses. Presumbly, this activity is due to its ability to bind to DNA, resulting in strand scission with eleimination of purine and pyrimidine bases.
  • Bleomycin is reconstituted in normal saline solution at concentrations of 0.5 U/mL to 1 U/mL.
  • the resulting reconstituted solution reportedly retains 90% activity for 4 weeks if refrigerated.
  • Use of lower concentration of 0.5 U/mL does not seem to diminish the response when compared with that of higher concentrations.
  • Optimal results are obtained when the intralesional injection results in blanching of the wart.
  • individual treatments are limited to 2 mL of total volume or 1.5 total U of bleomycin solution, with a maximum of 1 mL used for any single wart. More-specific guidelines for actual volumes injected, varying with the size of the warts, have been published.
  • a positive response is usually indicated by formation of a black eschar, which can be pared away. Repeated treatments, up to a total of three or four, may be repeated at 2-to 4 week intervals. Inadvertently too deep placement of the needle can affect success adversely and result in local neerosis.
  • Advantages to the use of bleomycin include successful treatment of otherwise difficult-to-treat lesions, particularly periungual and plantar warts, with little or no scarring. Disadvantages to treatment using this modality are largely related to cost, potential side effects,. Pain is common during injection of bleomycin but reportedly is comparable to that experienced with the use of liquid nitrogen.
  • Dinitrochlorobenzene is a potent sensitizing agent that has been used for the treatment of recalcitrant warts for nearly 20 years.
  • DNCB has several explanations for the mechanism of action of DNCB.
  • One theory is that the wart is destroyed as an "innocent bystander" by the contact dermatitis induced by DNCB.
  • a more specific theory is the DNCB attaches to wart protein and an immune response to the wart itself is triggered.
  • Treatment involves sensitizing the patient to the DNCB by applying it is normal skin often on the inner aspect of the upper arm. Patch testing to DNCB is then carried out approximately 2 weeks later to establish that sensitization has occurred.
  • the warts are then treated with a daily application of DNCB at home or at 2- week intervals in the physician's office.
  • the concentration and frequency of application of the DNCB must be adjusted to, produced a moderate degree of pruritus, edema, and erythema without excessive discomfort to the patient. Success rates as high as 90% have been reported.
  • the most common complication is excessive irritation of the wart.
  • Some patients will develop hyperpigmentation or hypopigmentation at the area of primary sensitization, and this is the reason that it is best to use an inconspicuous site so that there is not a cosmetic problem for the patient.
  • Another problem with DNCB sensitization is the possibility of developing cross-reactions with and contact dermatitis to other chemically related substances.
  • Dinitrochlorobenzene does cross-react with nitrobenzene compounds, which are used in the chemical and agricultural industries as well as in laboratories.
  • DNCB has been associated with a positive Ames test for mutagenicity, and there is a concern it might be a carcinogen.
  • Dinitrochlorobenzene is a difficult therapy for both the physician and the patient. Therefore, it is used primarily for warts that are resistant to all other treatments, especially those of the periungual area. Considerable expertise and caution are required when one is embarking on its use. Considering the numerous treatment options we have at our disposal for eradication of warts we are still far from an optimum treatment, thus there is definitely a scope in developing newer treatment method for optimization.
  • the present invention comprises of two carrier system (1) Soluble sulfide of alkali or alkaline earth metals or a combination thereof in an non aqueous or aqueous polar or semi polar solvent in an inert atmosphere and (2)Eutectic mixture of Lidocaine and Prilocaine in an oil in water emulsion to be used for topical painless treatment of various dermatological conditions characterized by massive hyperkeratosis including but not limiting to Warts, corns and callus.
  • Sulfides - Sulfides have been used in topical dermatological condition for over a century for their having the properties of keratosolvent that is they dissolve the keratinous material forming the outermost layer of the skin, beside this sulfides also have antiparasitic and antibacterial properties.
  • the difficulty in stabilization has always remained a major problem in their commercialization.
  • U.S. Pat. No. 5,585,398 and U.S. Pat. No. 5,942,543 issued to Amy A. Ernst describes a topical, anesthetic composition comprising lidocaine, adrenaline and tetracaine in either a gel base or an aqueous base, respectively.
  • the present composition is free of Adrenaline.
  • U.S. Pat. No. 6,429,228 Bl issued to Toshio Inage et al. describes a local anesthetic composition for external use comprising lidocaine or prilocaine and salts thereof, a percutaneous absorption accelerator such as caprylic acid, ethanol and/or isopropyl alcohol, and water.
  • a percutaneous absorption accelerator such as caprylic acid, ethanol and/or isopropyl alcohol
  • U.S. Pat. No. 4,830,633 issued of 1989, to Yutaka Hori et al. describes a depilation method including the coating of a depilatory agent containing an aqueous solution or emulsion of thiolglycolic acid or salt thereof, strontium sulfate, and sodium sulfide or potassium sulfide.
  • the composition is distinguishable for requiring thioglycolic acid and numerous other substances.
  • U S patent 7364575 issued in 2008 comprises of a assembly for administration of painless Liquid Nitrogen therapy by applying topical anesthetic in treating of wart.
  • a sulfide of an alkali or alkaline earth metal is used as an keratosolvent agent in combination with topical anaesthetics .
  • the sulfide component in the composition dissolves the hyperkeratotic epidermis thereby facilitates the penetration of the topical anesthetic component which otherwise is not possible as it is well perceived that EMLA containing eutectic mixture of Lidocaine and Prilocaine does not produce the desired anesthesia when there is hyperkeratotic epidermis as that over the planter and palmer surface and in these areas the injections shots are more painful.
  • the present invention comprises of two carrier system (1) Soluble sulfide of an alkali or alkaline earth metals or a combination thereof in a polar and/or semi polar solvent in an inert atmosphere and (2) Eutectic mixture of Lidocaine and Prilocaine in an oil in water emulsion to be used for topical painless treatment of various dermatological conditions characterized by massive hyperkeratosis including but not limiting to Warts, corns and callus.
  • the nature of solution is highly basic ware the desired , pH can be maintained 8 to 14.
  • the sulfide component in the composition acts as a keratosolvent and enhances the penetration of the topical anesthetic component which facilitates painless removal of wart along with the surrounding keratotic tissue.
  • the subjects treatable by the inventive compositions and methods in preferred aspects are humans. In certain aspects, the subjects are children. In certain other aspects, the subjects are immunocompromised persons.
  • purified water has been used as the carrier for the sulfide component
  • the present invention provides a composition where glycerol has been used as carrier in an inert atmosphere provided with any suitable gas, such as nitrogen, helium,neon,argon or mixtures thereof.
  • the invention provides a combination of Glycerol, Di
  • Methyl Sulfoxide, Ethyl Alcohol or a mixture thereof in an inert atmosphere as a carrier for the alkaline component is a carrier for the alkaline component.
  • the invention provides a composition ware Polar solvent such as Di Methyl Sulfoxide has been used in an inert atmosphere as a carrier for the alkali metal
  • the invention provides a composition Ethyl Alcohol has been used as a carrier in an inert atmosphere.
  • Sulfurated Potash USP has been used to provide the polysulfide component.
  • prilocaine or tetracaine in base form is mixed with one of benzocaine, lidocaine, bupivacaine, mepivacaine, or etidocaine or tetracaine in base form. It is evident that when tetracaine is used as first base it can not be used as second base.
  • prilocaine and bensocaine are mixed in a weight ratio of 65:35 to 80:20, preferably 70:30.
  • prilocaine and lidocaine are mixed in a weight ratio of 42:56 to 80:20, preferably 47:53 to 62:38. According to another preferred embodiment prilocaine and etidocaine are mixed in a different effective weight ratio
  • prilocaine and bupivacaine are mixed in a different effective weight ratio
  • tetracaine and lidocaine in their base forms are mixed in a weight ratio.
  • the composition comprising of the carrier systems may contain gelling agents such as carbopol , viscosity enhancer may be added to any of the carrier system
  • composition might contain chelating agents such as EDTA ,perfuming agent such as lavender, citronella, benzyl alcohol, lemon grass, vanillin
  • the present invention comprises of two carrier system (1) Soluble sulfide of alkali or alkaline earth metals or a combination thereof in a polar and/or semi polar solvent in an inert atmosphere as a carrier and (2)Eutectic mixture of Lidocaine and Prilocaine in an oil in water emulsion to be used for topical painless treatment of various dermatological conditions characterized by massive hyperkeratosis including but not limiting to Warts, corns and callus.
  • the solution contain the active ingredients having pharmacological action namely keratosolvent and topical anesthesia , a small piece of cotton is soaked in the prepared solution, this soaked tissue is then left over the area to be treated covered with a polythene dressing, on removal the area under treatment gets softened ,this is then removed with the help of a razor blade or a curette.
  • active ingredients having pharmacological action namely keratosolvent and topical anesthesia
  • sulfide used was Sodium Sulfide which was provided as 10 % solution in Glycerol , this was mixed with an equal amount of emulsion containing of Prilocaine and of Lidocaine to provide 2.5 % of each topical anesthetics in an oil in water emulsion containing 2% Polyoxyethylene (used as an emulsifier) .
  • the patient in this experiment was a male aged 20 years having three warts on his foot all ware taken up for treatment at a single sitting, the two solution ware mixed and a small piece of cotton was then soaked in the prepared solution this soaked cotton was then left over the area to be treated covered with a polythene dressing to provide occlusion for lhour, on removal of the dressing the area appeared softened which was then scraped with the help of a razor blade or a curette.
  • the bleeding was controlled with pressure bandage, the bandage was changed on third day , the area healed up in a weeks time Experiment II.
  • the patient here was a female aged 50 years having 3 warts on her heel , the alcoholic solution of potassium polysulfide was mixed with the eutectic mixture of the topical anesthetic , cotton pads ware soaked in the solution of the two and placed over the watts for 1 hour under polythene covering on removal the warts got dissolved , the treated area was bandaged , a suitable oral antibiotic was given for 5 days, the dressing was changed on third and fifth day ,there was complete healing in a weeks time.
  • the composition used in this experimental study comprised of 5 % Sodium sulfide in purified water stored in an inert closure system, the eutectic component was the same 2.5 % of Lidocaine and Prilocaine in an oil in water containing 2% polyoxyethylene ester.
  • the occlusive dressing was kept for 30 minutes as the palmer epidermis is thinner than the sole. The dressing was removed the softened area was treated with pressure bandage for 5days. The area got normally epithelised. No recurrence was observed for over a period of 6 months.
  • the sulfide used in experiments is sodium sulfide
  • the amount of sulfides in our experimental studies preferably varied from varied from 5- 10 ,however , various strengths ranging from 1 -30 % of sulfides can be used percent
  • the percentage of the active ingredient sodium sulfide depends on the time for which the composition remains in contact with the skin , the higher the percentage lesser is the time required for dissolving the lesion , further the percentage of preferred concentration also depends thickness and hardening of the wart and the surrounding tissue.
  • BJD 1976; 94 :667 -79 reports 80% cure rate with Cryo in 2-4 sittings at 3 months Michael T.Goldfarb et al Office Therapy for human papilloma virus infection at non -genital sites Dermatologic Clinics Vol. 9, No.2 Aprill991 Pg 287-94 G.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention porte sur un système à deux supports : (1) du sulfure soluble d'alcali ou de métaux alcalinoterreux ou une combinaison de ceux-ci dans un solvant polaire et/ou semi-polaire dans une atmosphère inerte en tant que support et (2) un mélange eutectique de lidocaïne et de prilocaïne dans une émulsion huile-dans-eau devant être utilisée pour un traitement indolore topique de divers états dermatologiques caractérisés par une hyperkératose massive comprenant mais sans y être limitée les verrues, les cors et les durillons.
PCT/IN2010/000001 2009-01-07 2010-01-04 Traitement sans douleur des verrues, cors et durillons WO2010079513A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN20DE2009 2009-01-07
IN20/DEL/09 2009-01-07

Publications (2)

Publication Number Publication Date
WO2010079513A2 true WO2010079513A2 (fr) 2010-07-15
WO2010079513A3 WO2010079513A3 (fr) 2010-08-26

Family

ID=42316928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2010/000001 WO2010079513A2 (fr) 2009-01-07 2010-01-04 Traitement sans douleur des verrues, cors et durillons

Country Status (1)

Country Link
WO (1) WO2010079513A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018226894A1 (fr) 2017-06-06 2018-12-13 Verrica Pharmaceuticals, Inc. Traitement des troubles cutanés
US11052064B2 (en) 2013-08-21 2021-07-06 Verrica Pharmaceuticals Inc. Compositions, methods and systems for the treatment of cutaneous disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2202441B (en) * 1987-03-25 1990-07-18 William Keith Ross Watson Topical medicaments containing citric acid.
US6855342B2 (en) * 2000-06-30 2005-02-15 Medicis Pharmaceutical Corporation Compositions and methods for high sorption of skin materials and delivery of sulfur
US6514489B1 (en) * 2000-06-30 2003-02-04 Medicis Pharmaceutical Corp. Sulfur containing dermatological compositions and methods for reducing malodors in dermatological compositions
DE10164531A1 (de) * 2001-12-31 2003-07-17 Pharmatech Gmbh Zubereitung zur Oberflächenanästhesie der Haut

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11052064B2 (en) 2013-08-21 2021-07-06 Verrica Pharmaceuticals Inc. Compositions, methods and systems for the treatment of cutaneous disorders
WO2018226894A1 (fr) 2017-06-06 2018-12-13 Verrica Pharmaceuticals, Inc. Traitement des troubles cutanés
CN111278414A (zh) * 2017-06-06 2020-06-12 维里卡制药有限公司 皮肤病的治疗
JP2020522578A (ja) * 2017-06-06 2020-07-30 ヴェリカ ファーマシューティカルズ, インコーポレーテッドVerrica Pharmaceuticals, Inc. 皮膚障害の処置
EP3634370A4 (fr) * 2017-06-06 2021-03-03 Verrica Pharmaceuticals, Inc. Traitement des troubles cutanés
US11147790B2 (en) 2017-06-06 2021-10-19 Verrica Pharmaceuticals Inc. Treatment of cutaneous disorders
JP7280870B2 (ja) 2017-06-06 2023-05-24 ヴェリカ ファーマシューティカルズ インコーポレーテッド 皮膚障害の処置

Also Published As

Publication number Publication date
WO2010079513A3 (fr) 2010-08-26

Similar Documents

Publication Publication Date Title
Stulberg et al. Molluscum contagiosum and warts
US7833542B2 (en) Method and composition for the treatment of scars
US3549770A (en) Therapeutic administration of effective amounts of dimethyl sulfoxide to human and animal subjects
Goldfarb et al. Office therapy for human papillomavirus infection in nongenital sites
JP2012501348A (ja) ホメオパシー治療法
JPH0617299B2 (ja) ポビドン−沃素と糖を含む医薬組成物
US11696907B2 (en) Wound healing composition
WO2010079513A2 (fr) Traitement sans douleur des verrues, cors et durillons
US20140011838A1 (en) Compositions and methods for treating warts associated with viral infections
Kuflik Specific indications for cryosurgery of the nail unit: myxoid cysts and periungual verrucae
Das et al. Human papillomavirus infection: Management and treatment
ES2312421T3 (es) Composicion farmaceutica en gel.
CN1116885C (zh) 一种治疗痔疮的药物
JP6487459B2 (ja) アルテミシニンおよびその誘導体を使用する脂漏性角化症の処置若しくは予防
KUFLIK Cryosurgical treatment of periungual warts
JPH01230514A (ja) エアゾール型外用貼付剤
Jules et al. Nail infections
EP1218063B1 (fr) Composition pharmaceutique comprenant acide trichloracetique, 2-oh acide benzoique et menthol a usage topique et son procede de preparation
MXPA03006346A (es) Composiciones de cianoacrilato para el tratamiento profilactico o terapeutico de enfermedades que se manifiestan por si mismas en el tejido cutaneo y/o danan al mismo.
Baran et al. Treatment of Common Nail Disorders
Dhaon et al. Efficacy and Safety of Nimesulide Transdermal Gel versus Diclofenac and Piroxicarn Gel in Patients with Acute Musculoskeletal Condition
e Silva et al. Combined treatment for rhinophyma
WO2015048930A1 (fr) Composition pharmaceutique contenant du lornoxicam et de la povidone iodée
WO2004071516A1 (fr) Preparation percutanee contenant de la glycyrrhizine
Ricketti et al. Histofreezer®

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10729149

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10729149

Country of ref document: EP

Kind code of ref document: A2